NEKTAR THERAPEUTICS (NKTR) Stock
NKTR has an Alpha Score of 16 out of 100 (poor), computed on Nov 10, 2026 from 2 of 4 sub-scores. 1 member of Congress disclosed 2 trades in NKTR since 2018: 1 purchase and 1 sale, most recently Josh Gottheimer (sale, Jun 21, 2018). 4 of the hedge funds AlphaScala tracks reported NKTR in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $33.38M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 10, 2026.
What is NKTR's Alpha Score?
How it works →Alpha Score of 16 reflects poor overall profile with poor momentum, poor quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 10, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded NEKTAR THERAPEUTICS (NKTR)?
Most recent: Josh Gottheimer (sale, Jun 21, 2018); records start Jun 6, 2018.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Josh Gottheimer D-NJ · House | 2018-06-21 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2018-06-06 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 9, 2026.
See all NKTR political trades →Which hedge funds own NKTR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 478K | $33.38M | +18% |
| Citadel Ken Griffin | 160K | $11.15M | -69% |
| Blackstone | 29K | $2.00M | NEW |
| Marshall Wace | 3K | $230.4K | -98% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are NEKTAR THERAPEUTICS insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 18, 26 | Robin Howard W | President & CEO | SELL | 418 | $30K |
| Aug 18, 26 | Zalevsky Jonathan | Chief R&D Officer | SELL | 186 | $13K |
SEC Form 4 filings as of Nov 10, 2026
See cluster-buy signals across all tickers →What are NKTR's key statistics?
Key statistics as of Nov 10, 2026
How does NKTR's valuation compare with the Healthcare sector?
| Metric | NKTR | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -284.39% | 3.60% | 175 |
| Return on equity | -37.54% | 2.93% | 201 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 11, 2026). P/E excludes loss-making companies.
NKTR price chart
Powered by TradingViewWhat does NEKTAR THERAPEUTICS do?
Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and chronic inflammatory diseases in the United States and internationally. Its lead product candidate, rezpegaldesleukin (also known as REZPEG or NKTR-358), is a novel regulatory T cell stimulator and IL-2 pathway agonist designed to restore immune system balance in conditions such as moderate-to-severe atopic dermatitis, severe-to-very-severe alopecia areata, and Type 1 diabetes mellitus. The company is advancing rezpegaldesleukin through Phase 2b clinical trials, including the REZOLVE-AD and REZOLVE-AA studies, which evaluate subcutaneous injections for efficacy in disease control and patient outcomes. Beyond its lead asset, Nektar Therapeutics Inc. maintains a pipeline of investigational programs targeting immune pathways, such as a preclinical bivalent tumor necrosis factor receptor type II agonist, bispecific molecules NKTR-0165 and NKTR-0166, a modified hematopoietic colony stimulating factor protein NKTR-422, and NKTR-255, an IL-15 receptor agonist developed in collaboration for oncology applications to enhance anti-tumor immune responses. Founded in 1990 and headquartered in San Francisco, California, Nektar Therapeutics Inc. leverages expertise in polymer chemistry and immunology to create highly selective medicines addressing unmet needs in immunotherapy.